Inflammatory cytokine inhibition (null)

Inflammatory cytokine inhibition" is a therapeutic strategy encompassing a variety of approaches aimed at blocking the activity of pro-inflammatory cytokines or their receptors. These strategies include neutralizing antibodies, receptor antagonists, decoy receptors, and small molecule inhibitors that intervene in cytokine production or signaling pathways (such as JAK/STAT, NF-κB)[1][2][7][8]. The rationale is to reduce pathologic inflammation driving autoimmune and autoinflammatory diseases, cancer, and some cardiovascular disorders[2][4]. Commonly targeted cytokines are tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6), and interleukin-17 (IL-17)[2][5]. Drug classes include biologics (such as anti-TNF monoclonal antibodies and IL-1 receptor antagonists) and small molecule inhibitors (such as JAK inhibitors)[1][2][6][8]. Therapeutic inhibition of inflammatory cytokines can effectively decrease disease activity and tissue damage but risks compromising host defense, leading to increased infections and possible other immune-related complications[2][4][8]. Newer approaches seek to localize cytokine inhibition to sites of inflammation to minimize systemic side effects[2]. In summary, "inflammatory cytokine inhibition" should not be catalogued as a molecular target; it is an umbrella term for pharmacological modulation of a set of cytokines and their signaling pathways implicated in pathogenic inflammation.

Other names

inhibition of pro-inflammatory cytokinesanti-cytokine therapycytokine blockadecytokine neutralization

Neutralization of pro-inflammatory cytokines (e.g., using antibodies against TNF-α, IL-1, IL-6, IL-17); Blockade of cytokine receptors (e.g., IL-1 receptor antagonist); Inhibition of intracellular signal transduction pathways (e.g., JAK/STAT, NF-κB); Decreased leukocyte activation and chemotaxis.